

TODAY IMPACTS TOMORROW'S CHOICES



How will you optimise
the treatment sequence
**FOR YOUR NSCLC
EGFR M+ PATIENTS?***



Scan to watch
the GioTag final analysis

EGFR M+, epidermal growth factor receptor mutation positive;
NSCLC, non-small cell lung cancer

*Patients who acquire a T790M mutation on progression with **GIOTRIF®**
in 1st-line



**Boehringer
Ingelheim**

Boehringer Ingelheim Singapore Pte. Ltd.

128 Beach Road

#11-01 Guoco Midtown, Singapore 189773

Phone: +65 / 6419 8600

Fax: +65 / 6297 5771



GIOTRIF®
(afatinib) tablets



Scan QR code to access **GIOTRIF®**
latest prescribing information

EM-SG-100100 June 2023

For Healthcare Professionals Only